What this means
This is a trial that is still signing up patients, so no results are posted yet. It does not tell us yet whether the treatment works or is safe for older adults.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 75–100
- Where
- 1 site
The science
- Registered title
- Chemoradiotherapy in Elderly Patients With Oesophagus Cancer
- Trial ID
- NCT02735057 ↗
- Phase
- PHASE 1 / PHASE 2
- Study type
- interventional
- Conditions
- Oesophagus Cancer, Elderly Patients
- What is tested
- Carboplatin
- Sponsor
- Centre Hospitalier Universitaire de Besancon
- Ages
- 75 Years to 100 Years
- Dates
- First posted Apr 12, 2016 · updated Jan 18, 2024
Registry summary
Management of elderly patient with cancer is a therapeutic challenge and a public health problem. The mean age of esophageal cancer is 64.5 years and 72.1 years in men and women respectively. Surgery is a standard treatment reserved to about 30 % of patients. The other 70 % are considered unfit for surgery for various reasons, including ageing.
Chemoradiotherapy (CRT) is standard treatment for patients with esophageal cancer unfit for surgery. The validated treatment scheme is external beam radiotherapy (EBRT) 50 Gy over 5 weeks combined with cisplatin and 5FU infusion. However it induces high rates of severe and life threatening toxicities: grade 3 haematologic and esophageal mucositis of 20 and 25 % respectively, in patients with a median age of 64 years. CRT has not been properly evaluated in patients more than 75 years, and other combined chemotherapy are challenging.
Sites (1)
- Centre Hospitalier Universitaire de Besançon, Besançon, France